source
- BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demandBioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…
- Pathos AI signs two cancer deals, including $2 bn contract with China's Alphamab and partnership with AstraZenecaPathos AI announced two new collaborations to expand its oncology pipeline, one with AstraZeneca and another with a subsidiary of China's Alphamab Oncology. The deal with Jiangsu Alphamab Biopharm…